{"id":49746,"date":"2022-10-18T15:02:49","date_gmt":"2022-10-18T13:02:49","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/aerin-medical-announces-establishment-of-a-new-cpt-code-for-endoscopic-destruction-of-the-posterior-nasal-nerve-using-radiofrequency-ablation\/"},"modified":"2022-10-18T15:02:49","modified_gmt":"2022-10-18T13:02:49","slug":"aerin-medical-announces-establishment-of-a-new-cpt-code-for-endoscopic-destruction-of-the-posterior-nasal-nerve-using-radiofrequency-ablation","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/aerin-medical-announces-establishment-of-a-new-cpt-code-for-endoscopic-destruction-of-the-posterior-nasal-nerve-using-radiofrequency-ablation\/","title":{"rendered":"Aerin Medical Announces Establishment of a New CPT\u00ae Code for Endoscopic Destruction of the Posterior Nasal Nerve Using Radiofrequency Ablation"},"content":{"rendered":"
\n

\nProcedure Regularly Used by ENT Physicians Treating Chronic Rhinitis Patients<\/i>\n<\/p>\n

MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–#DefeatTheDrip<\/a>—Aerin Medical Inc.<\/a>, a company dedicated to providing Ear, Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, announced that the American Medical Association (AMA) Current Procedural Terminology (CPT\u00ae<\/sup>) Editorial Panel accepted the application for a new Category I CPT code to report endoscopic destruction of the posterior nasal nerve using radiofrequency (RF) ablation. This information was released by the AMA in the Summary of Panel Actions from the September CPT Editorial Panel meeting. The new code will become effective on January 1, 2024, and describes the procedure performed by ENT physicians when treating their patients with Aerin Medical\u2019s RhinAer\u00ae<\/sup>. The RhinAer Stylus precisely applies RF energy to overactive nerves in the back of the nose, reducing chronic rhinitis symptoms.\n<\/p>\n

<\/a>
<\/a><\/p>\n

\n\u201cA new CPT code is an important milestone for ENT physicians and their patients, enabling appropriate valuation and improving access to this transformative solution that can be readily performed in the physician office setting,\u201d said Matt Brokaw, CEO of Aerin Medical. \u201cWe appreciate the otolaryngology society leadership and physician investigator commitment to generating robust clinical evidence for the RF approach, including the longest-term published randomized controlled trial data available.\u201d\n<\/p>\n

\nThe company recently announced<\/a> the launch of a next-generation RhinAer Stylus designed to provide physicians with improved visualization, as well as easier access and tissue apposition, especially in patients with narrow nasal airways.\n<\/p>\n

\nAbout RhinAer<\/b>\n<\/p>\n

\nUsing temperature-controlled, radiofrequency technology, RhinAer features a thin, wand-like stylus that is inserted via the nostril to deliver precise therapeutic benefits, while sparing surrounding tissues. RhinAer directly disrupts the posterior nasal nerve (PNN) that triggers excessive mucus production, treating an underlying cause of chronic rhinitis. RhinAer provides ENT physicians with a comprehensive solution for the treatment of chronic rhinitis, addressing sources of rhinorrhea (runny nose) and congestion. RhinAer initially received FDA 510(k) clearance in December 2019 and CE Mark in 2020. For more information, visit www.RhinAer.com<\/a>.\n<\/p>\n

\nAbout Aerin Medical<\/strong>\n<\/p>\n

\nAerin Medical is a privately held, venture-backed company, with U.S. offices in California and Texas. Aerin\u2019s mission is to provide ENT physicians with non-invasive solutions for the treatment of chronic nasal conditions. The company\u2019s products, VivAer\u00ae<\/sup> for nasal airway obstruction and RhinAer\u00ae<\/sup> for chronic rhinitis, leverage Aerin\u2019s proprietary temperature-controlled technology, which allows ENT physicians to reliably improve patients\u2019 symptoms with in-office procedures performed with local anesthetic. More than 60,000 patients have been treated with Aerin Medical products to date. For more information, please visit www.aerinmedical.com<\/a> and follow Aerin Medical on Facebook<\/a>, Twitter<\/a>, Instagram<\/a>, LinkedIn<\/a> and YouTube<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nKeshia Cain
\n
573-517-1593
\n
keshia@merrymancommunications.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Procedure Regularly Used by ENT Physicians Treating Chronic Rhinitis Patients MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–#DefeatTheDrip—Aerin Medical Inc., a company dedicated to providing Ear, Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, announced that the American Medical Association (AMA) Current Procedural Terminology (CPT\u00ae) Editorial Panel accepted the application for a … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-49746","6":"format-standard","7":"category-industry"},"yoast_head":"\nAerin Medical Announces Establishment of a New CPT\u00ae Code for Endoscopic Destruction of the Posterior Nasal Nerve Using Radiofrequency Ablation - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/aerin-medical-announces-establishment-of-a-new-cpt-code-for-endoscopic-destruction-of-the-posterior-nasal-nerve-using-radiofrequency-ablation\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aerin Medical Announces Establishment of a New CPT\u00ae Code for Endoscopic Destruction of the Posterior Nasal Nerve Using Radiofrequency Ablation - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Procedure Regularly Used by ENT Physicians Treating Chronic Rhinitis Patients MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–#DefeatTheDrip—Aerin Medical Inc., a company dedicated to providing Ear, Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, announced that the American Medical Association (AMA) Current Procedural Terminology (CPT\u00ae) Editorial Panel accepted the application for a ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/aerin-medical-announces-establishment-of-a-new-cpt-code-for-endoscopic-destruction-of-the-posterior-nasal-nerve-using-radiofrequency-ablation\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-18T13:02:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221018005272\/en\/1604565\/21\/600_x_600_Console_and_RhinAer_Stylus_2.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aerin-medical-announces-establishment-of-a-new-cpt-code-for-endoscopic-destruction-of-the-posterior-nasal-nerve-using-radiofrequency-ablation\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aerin-medical-announces-establishment-of-a-new-cpt-code-for-endoscopic-destruction-of-the-posterior-nasal-nerve-using-radiofrequency-ablation\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Aerin Medical Announces Establishment of a New CPT\u00ae Code for Endoscopic Destruction of the Posterior Nasal Nerve Using Radiofrequency Ablation\",\"datePublished\":\"2022-10-18T13:02:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aerin-medical-announces-establishment-of-a-new-cpt-code-for-endoscopic-destruction-of-the-posterior-nasal-nerve-using-radiofrequency-ablation\\\/\"},\"wordCount\":464,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aerin-medical-announces-establishment-of-a-new-cpt-code-for-endoscopic-destruction-of-the-posterior-nasal-nerve-using-radiofrequency-ablation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221018005272\\\/en\\\/1604565\\\/21\\\/600_x_600_Console_and_RhinAer_Stylus_2.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aerin-medical-announces-establishment-of-a-new-cpt-code-for-endoscopic-destruction-of-the-posterior-nasal-nerve-using-radiofrequency-ablation\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aerin-medical-announces-establishment-of-a-new-cpt-code-for-endoscopic-destruction-of-the-posterior-nasal-nerve-using-radiofrequency-ablation\\\/\",\"name\":\"Aerin Medical Announces Establishment of a New CPT\u00ae Code for Endoscopic Destruction of the Posterior Nasal Nerve Using Radiofrequency Ablation - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aerin-medical-announces-establishment-of-a-new-cpt-code-for-endoscopic-destruction-of-the-posterior-nasal-nerve-using-radiofrequency-ablation\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aerin-medical-announces-establishment-of-a-new-cpt-code-for-endoscopic-destruction-of-the-posterior-nasal-nerve-using-radiofrequency-ablation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221018005272\\\/en\\\/1604565\\\/21\\\/600_x_600_Console_and_RhinAer_Stylus_2.jpg\",\"datePublished\":\"2022-10-18T13:02:49+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aerin-medical-announces-establishment-of-a-new-cpt-code-for-endoscopic-destruction-of-the-posterior-nasal-nerve-using-radiofrequency-ablation\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aerin-medical-announces-establishment-of-a-new-cpt-code-for-endoscopic-destruction-of-the-posterior-nasal-nerve-using-radiofrequency-ablation\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aerin-medical-announces-establishment-of-a-new-cpt-code-for-endoscopic-destruction-of-the-posterior-nasal-nerve-using-radiofrequency-ablation\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221018005272\\\/en\\\/1604565\\\/21\\\/600_x_600_Console_and_RhinAer_Stylus_2.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221018005272\\\/en\\\/1604565\\\/21\\\/600_x_600_Console_and_RhinAer_Stylus_2.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aerin-medical-announces-establishment-of-a-new-cpt-code-for-endoscopic-destruction-of-the-posterior-nasal-nerve-using-radiofrequency-ablation\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aerin Medical Announces Establishment of a New CPT\u00ae Code for Endoscopic Destruction of the Posterior Nasal Nerve Using Radiofrequency Ablation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aerin Medical Announces Establishment of a New CPT\u00ae Code for Endoscopic Destruction of the Posterior Nasal Nerve Using Radiofrequency Ablation - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/aerin-medical-announces-establishment-of-a-new-cpt-code-for-endoscopic-destruction-of-the-posterior-nasal-nerve-using-radiofrequency-ablation\/","og_locale":"en_US","og_type":"article","og_title":"Aerin Medical Announces Establishment of a New CPT\u00ae Code for Endoscopic Destruction of the Posterior Nasal Nerve Using Radiofrequency Ablation - Pharma Trend","og_description":"Procedure Regularly Used by ENT Physicians Treating Chronic Rhinitis Patients MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–#DefeatTheDrip—Aerin Medical Inc., a company dedicated to providing Ear, Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, announced that the American Medical Association (AMA) Current Procedural Terminology (CPT\u00ae) Editorial Panel accepted the application for a ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/aerin-medical-announces-establishment-of-a-new-cpt-code-for-endoscopic-destruction-of-the-posterior-nasal-nerve-using-radiofrequency-ablation\/","og_site_name":"Pharma Trend","article_published_time":"2022-10-18T13:02:49+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221018005272\/en\/1604565\/21\/600_x_600_Console_and_RhinAer_Stylus_2.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/aerin-medical-announces-establishment-of-a-new-cpt-code-for-endoscopic-destruction-of-the-posterior-nasal-nerve-using-radiofrequency-ablation\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/aerin-medical-announces-establishment-of-a-new-cpt-code-for-endoscopic-destruction-of-the-posterior-nasal-nerve-using-radiofrequency-ablation\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Aerin Medical Announces Establishment of a New CPT\u00ae Code for Endoscopic Destruction of the Posterior Nasal Nerve Using Radiofrequency Ablation","datePublished":"2022-10-18T13:02:49+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/aerin-medical-announces-establishment-of-a-new-cpt-code-for-endoscopic-destruction-of-the-posterior-nasal-nerve-using-radiofrequency-ablation\/"},"wordCount":464,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/aerin-medical-announces-establishment-of-a-new-cpt-code-for-endoscopic-destruction-of-the-posterior-nasal-nerve-using-radiofrequency-ablation\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221018005272\/en\/1604565\/21\/600_x_600_Console_and_RhinAer_Stylus_2.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/aerin-medical-announces-establishment-of-a-new-cpt-code-for-endoscopic-destruction-of-the-posterior-nasal-nerve-using-radiofrequency-ablation\/","url":"https:\/\/pharma-trend.com\/en\/aerin-medical-announces-establishment-of-a-new-cpt-code-for-endoscopic-destruction-of-the-posterior-nasal-nerve-using-radiofrequency-ablation\/","name":"Aerin Medical Announces Establishment of a New CPT\u00ae Code for Endoscopic Destruction of the Posterior Nasal Nerve Using Radiofrequency Ablation - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/aerin-medical-announces-establishment-of-a-new-cpt-code-for-endoscopic-destruction-of-the-posterior-nasal-nerve-using-radiofrequency-ablation\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/aerin-medical-announces-establishment-of-a-new-cpt-code-for-endoscopic-destruction-of-the-posterior-nasal-nerve-using-radiofrequency-ablation\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221018005272\/en\/1604565\/21\/600_x_600_Console_and_RhinAer_Stylus_2.jpg","datePublished":"2022-10-18T13:02:49+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/aerin-medical-announces-establishment-of-a-new-cpt-code-for-endoscopic-destruction-of-the-posterior-nasal-nerve-using-radiofrequency-ablation\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/aerin-medical-announces-establishment-of-a-new-cpt-code-for-endoscopic-destruction-of-the-posterior-nasal-nerve-using-radiofrequency-ablation\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/aerin-medical-announces-establishment-of-a-new-cpt-code-for-endoscopic-destruction-of-the-posterior-nasal-nerve-using-radiofrequency-ablation\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221018005272\/en\/1604565\/21\/600_x_600_Console_and_RhinAer_Stylus_2.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221018005272\/en\/1604565\/21\/600_x_600_Console_and_RhinAer_Stylus_2.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/aerin-medical-announces-establishment-of-a-new-cpt-code-for-endoscopic-destruction-of-the-posterior-nasal-nerve-using-radiofrequency-ablation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Aerin Medical Announces Establishment of a New CPT\u00ae Code for Endoscopic Destruction of the Posterior Nasal Nerve Using Radiofrequency Ablation"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49746","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=49746"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49746\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=49746"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=49746"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=49746"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}